Market Place
Sourcing Support
Junshi Biosciences Reveals 2025 Financials And Corporate Updates
13 Mar 2026 //
GLOBENEWSWIRE
Junshi Bio` sNDA for Toripalimab Accepted as Urothelial Carcinoma
08 Aug 2025 //
GLOBENEWSWIRE
Junshi Biosciences Announces 2024 Financial Results and Updates
28 Mar 2025 //
GLOBENEWSWIRE
Junshi Biosciences Announces Toripalimab Approval in Singapore
26 Mar 2025 //
GLOBENEWSWIRE
Junshi Announces EC Approval for Marketing of Toripalimab
24 Sep 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces 2024 Interim Financial Results
30 Aug 2024 //
GLOBENEWSWIRE
EMA CHMP Issues Positive Opinion On Junshi Biosciences` Toripalimab
26 Jul 2024 //
GLOBENEWSWIRE
Junshi`s Toripalimab Combo NDA Accepted For Liver Cancer
17 Jul 2024 //
GLOBENEWSWIRE
Junshi Biosciences Receives sNDA Approval for Toripalimab in Advanced TNBC
25 Jun 2024 //
GLOBENEWSWIRE
Junshi Announces sNDA Approval For Toripalimab in 1st-Line Lung Cancer
18 Jun 2024 //
GLOBENEWSWIRE
Junshi, Coherus move Loqtorzi closer to another approval
13 Jun 2024 //
FIERCE PHARMA
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
24 Apr 2024 //
GLOBENEWSWIRE
Junshi Bio Announces Approval of the sNDA for Toripalimab for Renal Cancer
07 Apr 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces Toripalimab™s NDA Accepted
01 Feb 2024 //
GLOBENEWSWIRE
Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyout
10 Jan 2024 //
ENDPTS
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab
19 Jul 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab
11 Jul 2023 //
GLOBENEWSWIRE
Junshi Announces Acceptance of sNDA for Toripalimab with Chemotherapy
23 May 2023 //
GLOBENEWSWIRE
Junshi Bio touts lung cancer data as it looks to expand PD-1 label in China
22 Apr 2023 //
ENDPTS
Junshi`s Lynparza rival hits mark in ovarian cancer phase 3
13 Apr 2023 //
FIERCE BIOTECH
Junshi Bio Announces Acceptance of the Supplemental NDA for Toripalimab
11 Apr 2023 //
GLOBENEWSWIRE
Junshi Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer
11 Apr 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces 2022 Full Year Financial Results
31 Mar 2023 //
GLOBENEWSWIRE
Junshi`s lipid lowering drug hits phase 3 goals
01 Mar 2023 //
FIERCE BIOTECH
Junshi & Coherus Announce Positive Final Overall Survival Results of JUPITER-02
15 Feb 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Approval for Marketing of VV116 in China
30 Jan 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces NEJM Publication of Results of Ph3 Study of VV116
29 Dec 2022 //
GLOBENEWSWIRE
Hikma & Junshi Biosciences sign exclusive licensing agreementfor cancer treatment drug toripalimab
27 Dec 2022 //
PRESS RELEASE
Junshi Announces data from Phase I study of anti-BTLA antibody Tifcemalimab
10 Dec 2022 //
GLOBENEWSWIRE
Junshi Announces Submission of a MAA for Toripalimab to UK the Medicines
24 Nov 2022 //
GLOBENEWSWIRE
Junshi Announces Approval of Supplemental Application for Adalimumab
21 Nov 2022 //
GLOBENEWSWIRE
Junshi Announces Submission of a Marketing Authorization EMAfor Toripalimab
14 Nov 2022 //
GLOBENEWSWIRE
Junshi Biosciences & Coherus Announce Publication of +ve Results from CHOICE-01
12 Oct 2022 //
GLOBENEWSWIRE
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination
20 Sep 2022 //
GLOBENEWSWIRE
Junshi Biosciences Announces 2022 Interim Financial Results
30 Aug 2022 //
GLOBENEWSWIRE
Junshi Announces FDA Approval of Investigational New Drug Application for JS110
25 Aug 2022 //
GLOBENEWSWIRE
Junshi Announces Acceptance of Supplemental Application for Adalimumab Injection
17 Aug 2022 //
GLOBENEWSWIRE
Junshi Biosciences Receives Orphan Designation from the EC for Toripalimab
21 Jul 2022 //
GLOBENEWSWIRE
Two months after CRL, FDA accepts Coherus, Junshi`s resubmission of Toripalimab
07 Jul 2022 //
ENDPTS
Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology at ASCO
06 Jun 2022 //
GLOBENEWSWIRE
I-Mab, Junshi`s cancer combo worked best as first-line treatment
28 May 2022 //
FIERCEBIOTECH
Junshi reports positive Phase III data in mild-to-moderate Covid-19
24 May 2022 //
CLINICALTRIALSARENA
Junshi Nabs NMPA Approval of sNDA for Toripalimab plus Paclitaxel and Cisplatin
16 May 2022 //
GLOBENEWSWIRE
FDA rejects two China-developed cancer drugs
03 May 2022 //
BIOPHARMADIVE
Junshi Bio, Coherus Present Results of PIII Study of Toripalimab at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Junshi Bio Nabs FDA Approval of IND for Anti-CD112R MAb in Advanced Solid Tumors
04 Apr 2022 //
GLOBENEWSWIRE
Junshi Biosciences Announces Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Junshi Bio Begins Dosing in China in P III Trial of VV116 in COVID-19
16 Mar 2022 //
GLOBENEWSWIRE
PDS Bio Achieves Enrollment Objective in NCI-Led PII Trial of PDS0101
15 Mar 2022 //
GLOBENEWSWIRE
Coherus, Junshi Announce Positive Results from Phase 3 Esophageal Cancer Study
04 Mar 2022 //
GLOBENEWSWIRE
Junshi Bio, Coherus Expand Immuno-Oncology Collaboration for TIGIT-Targeted Ab
10 Jan 2022 //
GLOBENEWSWIRE
Junshi and Coherus plan to hustle the latest PD-1 to the FDA
14 Dec 2021 //
STREETINSIDER
Junshi and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab
01 Nov 2021 //
BIOSPACE
Junshi & Coherus Announce FDA Acceptance of BLA Toripalimab
01 Nov 2021 //
GLOBENEWSWIRE
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA & TUOYI
20 Sep 2021 //
GLOBENEWSWIRE
Junshi Announces Expansion of EUA for Etesevimab and Bamlanivimab
19 Sep 2021 //
GLOBENEWSWIRE
Junshi and Coherus to Present Overall Survival Results from JUPITER-06
17 Sep 2021 //
GLOBENEWSWIRE
Coherus and Junshi Biosciences to Present Results from JUPITER-06 Clinical Trial
16 Sep 2021 //
GLOBENEWSWIRE
Coherus & Junshi Data on Toripalimab Publshed in Nature Medicine
15 Sep 2021 //
GLOBENEWSWIRE
Coherus & Junshi to submit BLA of Toripalimab in Nasopharyngeal Carcinoma to FDA
01 Sep 2021 //
GLOBENEWSWIRE
